In re Jiangbo Pharmaceuticals, Inc.
884 F. Supp. 2d 1243
S.D. Fla.2012Background
- Lead Plaintiffs sue Jiangbo, Frazer, Sung, and others in a federal securities class action alleging violations of the 10(b) and 20(a) provisions and Rule 10b-5.
- Jiangbo is a Florida holding company with operations in China; Frazer audited Jiangbo until 2011 and Sung served as CFO until March 2011 and later as a consultant.
- Plaintiffs allege Jiangbo overstated cash balances, failed to disclose a related-party $31 million Hilead transfer, undisclosed internal SEC/audit investigations, and misstatements related to GAAP/GAAS.
- A series of debt defaults (2007 and 2008 debentures) and subsequent waivers and renegotiations are framed as indicators of misstatements and financial distress.
- Jiangbo's stock trades on NASDAQ halted on May 31, 2011 amid disclosures of investigations; the company later filed restatements and amendments.
- Defendants move to dismiss the Consolidated Amended Complaint; Jiangbo is in default for failure to appear; court adopts briefing and grants the motions, allowing amendment without prejudice.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether cash overstatement allegations are pleaded with particularity | CAC alleges specific statements, timing, and reasons cash was overstated, with supporting conduct (internal investigation issues, defaults). | Sung argues no precise amounts, responsible parties, or knowledge shown; post-resignation statements are improperly tied to her. | Plaintiff failed to plead strong inference of scienter; cash overstatement pleaded insufficiently against Sung. |
| Whether Hilead related-party disclosure was required and pled | Item 404 requires disclosure of related-party transactions exceeding $120,000; Hilead not disclosed is alleged. | Plaintiffs did not allege Jiangbo was a party to the Hilead transaction or when it occurred. | Non-disclosure claim insufficiently pled; no duty to disclose established. |
| Whether accounts receivable overstating and GAAP/GAAS issues support scienter | Frazer's GAAP/GAAS violations and overstated receivables show fraud indicators; auditor ignored red flags. | GAAP/GAAS violations alone do not establish scienter; no glaring red flags or auditor involvement shown. | Scienter not sufficiently pled against Sung or Frazer; no strong inference of fraud established at this stage. |
| Whether loss causation is adequately pled | Disclosures of investigations and defaults, followed by stock drops, show loss causation through partial disclosures. | Challenge to causation tied to the asserted misstatements and timing; disputes on linkage. | Loss causation pleadings sufficient; market reactions after disclosures support causation findings. |
| Whether group pleading extends to post-resignation statements by Sung | Group pleading doctrine implicates Sung in group statements notwithstanding resignation. | After March 31, 2011 Sung’s involvement in day-to-day statements is minimal; group pleading insufficient. | Post-resignation liability not sufficiently pled; Sung not liable for statements after resignation. |
Key Cases Cited
- Hubbard v. BankAtlantic Bancorp, Inc. Sec. Litig., 625 F. Supp. 2d 1267 (S.D. Fla. 2008) (sufficient pleading when plaintiffs specify misstatements and reliance with details)
- In re Sunterra Corp. Sec. Litig., 199 F. Supp. 2d 1308 (M.D. Fla. 2002) (GAAP/GAAS violations with red flags support scienter when coupled with other factors)
- In re Hamilton Bankcorp., Inc. Sec. Litig., 194 F. Supp. 2d 1353 (S.D. Fla. 2002) (auditor’s pervasive failures can support scienter finding)
- Tellabs, Inc. v. Makar Issues & Rights, Ltd., 551 U.S. 308 (U.S. 2007) (strong inference standard requires cogent inference at least as compelling as opposing)
- Mizzaro v. Home Depot, Inc., 544 F.3d 1230 (11th Cir. 2008) (pleading scienter requires facts giving rise to a strong inference for each defendant)
- Phillips v. Scientific-Atlanta, Inc., 374 F.3d 1015 (11th Cir. 2004) ( PSLRA requires particularity for misstatements and omissions)
- Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (U.S. 2005) (loss causation requires causal connection between misrepresentation and loss)